Illumina, Inc. (NASDAQ:ILMN) Given Average Rating of "Hold" by Brokerages

Key Points

• Illumina received a consensus “Hold” rating from 18 brokerages: 10 analysts rated it a buy, six a hold and two a sell. The average 12-month price target is $199.13, while recent targets range from $205 to $260.
• Illumina exceeded quarterly expectations, reporting adjusted EPS of $1.31 versus the $1.23 consensus and revenue of $1.16 billion, up 9.4% year over year. Management’s fiscal 2026 EPS guidance is $5.30–$5.40.
• The stock opened at $206.45, with a $31.17 billion market capitalization, while insiders sold approximately $436.6 million of shares over the past 90 days; institutional investors own 89.42% of the company.

Illumina, Inc. (NASDAQ:ILMN - Get Free Report) has been assigned an average recommendation of "Hold" from the eighteen brokerages that are currently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and ten have assigned a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $199.1250.

Several brokerages have recently commented on ILMN. Canaccord Genuity Group raised their target price on shares of Illumina from $190.00 to $205.00 and gave the stock a "hold" rating in a report on Monday, August 3rd. Piper Sandler reiterated an "overweight" rating and issued a $225.00 price target (up from $200.00) on shares of Illumina in a research note on Monday, August 3rd. TD Cowen increased their price target on Illumina from $192.00 to $210.00 and gave the stock a "hold" rating in a research report on Friday, July 31st. Evercore restated an "outperform" rating on shares of Illumina in a research note on Monday, July 6th. Finally, UBS Group began coverage on Illumina in a report on Wednesday. They issued a "buy" rating and a $260.00 price objective for the company.

Illumina Stock Performance

Shares of ILMN stock opened at $206.45 on Friday. Illumina has a 52 week low of $88.00 and a 52 week high of $231.81. The company has a market capitalization of $31.17 billion, a price-to-earnings ratio of 38.52, a PEG ratio of 2.85 and a beta of 1.46. The company has a 50-day simple moving average of $200.89 and a 200 day simple moving average of $162.18. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same period last year, the business posted $1.19 earnings per share. The business's revenue for the quarter was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, sell-side analysts predict that Illumina will post 5.36 earnings per share for the current year.

Insider Buying and Selling at Illumina

In other news, SVP Christensen Wedel sold 1,033 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the transaction, the senior vice president owned 14,023 shares of the company's stock, valued at approximately $2,685,684.96. This represents a 6.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith Meister sold 119,501 shares of the company's stock in a transaction on Friday, September 4th. The stock was sold at an average price of $218.40, for a total transaction of $26,099,018.40. Following the transaction, the director owned 770,350 shares of the company's stock, valued at $168,244,440. This trade represents a 13.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 2,062,465 shares of company stock valued at $436,589,802 over the last 90 days. Corporate insiders own 2.90% of the company's stock.

Institutional Trading of Illumina

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Elyxium Wealth LLC bought a new position in Illumina in the 4th quarter valued at approximately $25,000. Fiduciary Financial Advisors bought a new stake in Illumina during the 2nd quarter worth approximately $26,000. MCF Advisors LLC grew its holdings in Illumina by 172.4% during the 2nd quarter. MCF Advisors LLC now owns 158 shares of the life sciences company's stock worth $28,000 after acquiring an additional 100 shares during the last quarter. Keating Financial Advisory Services Inc. acquired a new position in Illumina in the 2nd quarter valued at approximately $32,000. Finally, Quarry LP acquired a new position in Illumina in the 3rd quarter valued at approximately $32,000. 89.42% of the stock is currently owned by institutional investors.

Illumina Company Profile

Illumina, Inc develops and manufactures genomic analysis technologies used by researchers, healthcare providers, pharmaceutical companies and other organizations. Its offerings include next-generation DNA sequencing systems, microarray platforms, consumables, laboratory services and bioinformatics software designed to help analyze genetic variation and biological functions.

The company's sequencing instruments include systems for a range of applications and throughput levels, such as the NovaSeq, NextSeq, MiSeq and iSeq platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.